South Korea-based startup Lunit, a leading medical AI provider, has raised $61 million in its Pre-IPO fundraising round ahead of the company's planned public offering on the South Korean stock market (KOSDAQ) early next year.

A number of new investors have joined the round including leading US healthcare investors HealthQuest Capital, Casdin Capital, and American Cancer Society BrightEdge, as well as Asia-based global healthcare investors Tybourne Capital Management, and NSG Ventures.

Prior to this latest round, Lunit closed a strategic investment of $26 million from Guardant Health last July. Combined with the pre-IPO round, the company has secured more than $135 million in total to date.

"Our purpose of the last few investment rounds has been to find partners who would bring strategic value for our future endeavours. Through these partnerships we look forward to reinforcing our journey to conquer cancer through AI," said Brandon Suh, CEO of Lunit.